Semaglutide is the most extensively documented GLP-1 peptide in modern research. Full profile: structure, mechanism, published titration and analytical documentation.
Semaglutide is a 31-residue GLP-1 analog with an Aib substitution at position 8 (DPP-4 resistance) and a C18 diacid spacer attached at Lys26 to enable reversible albumin binding. Average mass ~4113.6 Da.
Mechanism
Selective GLP-1 receptor agonism elevates intracellular cAMP in β-cells, drives glucose-dependent insulinotropic response, and modulates gastric emptying and central appetite circuits.
Published weekly titration reference
| Week | Reference weekly dose |
|---|---|
| 1–4 | 0.25 mg |
| 5–8 | 0.5 mg |
| 9–12 | 1.0 mg |
| 13–16 | 1.7 mg |
| 17+ | 2.4 mg |
Stability
Lyophilised semaglutide is documented as stable at −20 °C for 24+ months. Reconstituted material is documented as stable ~30 days at 2–8 °C when handled aseptically.
COA verification
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
